Plavix Sales Plummet With Generic Entry
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol estimates that “at risk” launch of generic clopidogrel impacted U.S. pharma sales by $525 mil. to $600 mil.
You may also be interested in...
Sanofi, EU Medicines Agencies Flag Acquired Hemophilia Link To Clopidogrel
Although only 12 cases have been reported to the company, extensive use of the anti-platelet drug and shortfalls in adverse event reporting systems mean the number could rise.
Feds Indict Former Bristol-Myers VP For Lying
Andrew Bodnar allegedly misled FTC on generic Plavix deal with Apotex.
Feds Indict Former Bristol-Myers VP For Lying
Andrew Bodnar allegedly misled FTC on generic Plavix deal with Apotex.